ALLR
Allarity Therapeutics, Inc.
Key Financials
Net Income
$-11231000
↑ 54.2%
Operating Income
$-12605000
↑ 53.7%
EPS (Diluted)
$-10.26
↓ 364.3%
Gross Profit
$-2265000
N/A
Total Liabilities
$8.4M
↓ 22.2%
Total Assets
$18.3M
↓ 19.4%
Long-term Debt
$2.7M
↑ 1.6%
Shareholders' Equity
$9.8M
↓ 16.8%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 10/1/2026 | View on SEC |
| 8-K | 9/29/2026 | View on SEC |
| 8-K | 9/16/2026 | View on SEC |
| 8-K | 9/14/2026 | View on SEC |
| 8-K | 8/14/2026 | View on SEC |
| 10-Q | 8/14/2026 | View on SEC |
| 8-K | 7/1/2026 | View on SEC |
| 8-K | 6/22/2026 | View on SEC |
| 8-K | 6/2/2026 | View on SEC |
| 10-Q | 5/15/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ALLR |
| Company Name | Allarity Therapeutics, Inc. |
| CIK | 1860657 |
| Sector | Pharmaceutical Preparations |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 401-426-4664 |